ERBB2 and breast carcinoma: Whilst most breast cancers are resistant to TRAIL induced apoptosis, it has recently been reported that mesenchymal breast cancer cell lines that lack hormone receptors (HER2 and ERα) respond to TRAIL treatment [18].